Home › Crohn's Disease › Rhode Island
Crohn's Disease clinical trials in Rhode Island
12 studies for Crohn's Disease are looking for participants at sites in Rhode Island.
Cities in Rhode Island
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University Gastroenterology - Providence - West River Street ( Site 5057), Providence
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- University Gastroenterology - Providence - Staniford Street /ID# 280919, Providence
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- University Gastroenterology, Providence
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology, Providence
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology Providence, Providence
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- University Gastroenterology, Providence
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology-Site Number: 8400103, Providence
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University Gastroenterology - GI Alliance-Site Number: 8400103, Providence
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University Gastroenterology, Providence
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Gastroenterology Associates, Providence
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Rhode Island Hospital, Providence
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Providence
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.